Noticias

PublicacionesTexto Científico

Bissa, M., et al. HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques. Nat Commun, 2025 Sep 29, 16(1):8571.

Bissa, M., et al. HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques. Nat Commun, 2025 Sep 29, 16(1):8571. PMID: 410...
Leer Más

Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China

Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China. Jiangsu Recbio Technology Co., Ltd. is ple...
Leer Más

Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192.

Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192. PMID: 40804241 This...
Leer Más

Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30.

Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30. PMID: 40737310 LeishTec is a recombin...
Leer Más

Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396.

Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396. PMI...
Leer Más

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, 61:127362.

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19)...
Leer Más

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, 10(1):184.

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. N...
Leer Más

Pallerla, S., et al. Scale-up and cGMP manufacturing of next-generation vaccine adjuvant Saponin/MPLA NanoParticles (SMNP). J Pharm Sci, 2025 Jul 19, 114(9):103913.

Pallerla, S., et al. Scale-up and cGMP manufacturing of next-generation vaccine adjuvant Saponin/MPLA NanoParticles (SMNP). J Pharm Sci, 2025 Jul 19, 114(9):103913. PMID:...
Leer Más
1 2 3 4 8

Start typing and press Enter to search